Crossmark

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas

Crossref DOI link: https://doi.org/10.1038/s41591-018-0006-x

Published Online: 2018-04-16

Published Print: 2018-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mount, Christopher W.

Majzner, Robbie G.

Sundaresh, Shree

Arnold, Evan P.

Kadapakkam, Meena

Haile, Samuel

Labanieh, Louai

Hulleman, Esther

Woo, Pamelyn J.

Rietberg, Skyler P.

Vogel, Hannes

Monje, Michelle https://orcid.org/0000-0002-3547-237X
Mackall, Crystal L. https://orcid.org/0000-0001-6323-4304
License Information

Text and Data Mining valid from 2018-04-16
More Information

Article History

Received: 5 June 2017

Accepted: 31 January 2018

First Online: 16 April 2018

Competing interests

: C.L.M, M.M., R.G.M. and C.W.M. are inventors on a patent application for GD2-directed CAR use for H3-K27M DMG.